Special Issue

Ion Channels as Pharmacological Targets in Cancer

Message from the Guest Editors

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Despite the significant advances in the identification and targeting of new molecular drivers of cancer, some of these targets have eluded drug treatments thus far. In this scenario, the targeting of ion channels has emerged as a promising novel approach in cancer treatment. Indeed, the altered expression and/or function of these proteins have been associated with tumor aggressiveness and increased proliferation, migration, invasion and metastasis of cancer cells. Furthermore, it has been demonstrated that ion channels are also involved in the control or sensing of the tumor microenvironment, in the development of chemoresistance and in the modulation of intracellular signaling. This evidence makes ion channels promising targets for fighting cancer through the identification of new pharmacological agents, drug repositioning and feasibly the use of target therapies, including monoclonal antibodies. The aim of this Special Issue is to publish original papers and reviews dealing with the role of ion channels in cancer progression, therapy and chemoresistance.

Guest Editors

Dr. Concetta Altamura

Dr. Ilaria Saltarella

Dr. Ester Pagano

Deadline for manuscript submissions

25 October 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/206351

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

